Sign in

CIK 0001778016

  • Non-accelerated filer

NovaBridge Biosciences

Sign in to watch
Ticker
NBP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
Cayman Islands
Entity type
Other
Phone
+1 301-670-2800
Business address
SUITE 400, 2440 RESEARCH BLVD, ROCKVILLE, MD, 20850
Former names
I-Mab
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$88,325
in 3 filings

Net −$88,325. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-10-15 Woo Ian Ying Director Option exercise +13,271 13,271
2026-10-15 Woo Ian Ying Director Option exercise · Restricted Share Units −5,770 11,540
2026-09-18 Dennis Phillip Andrew Chief Medical Officer Sale −8,209 $0.71 $6K 173,427
2026-09-17 Dennis Phillip Andrew Chief Medical Officer Option exercise +23,695 181,636
2026-09-17 Dennis Phillip Andrew Chief Medical Officer Option exercise · Restricted Share Units −10,302 72,120
2026-09-09 Cao Sean Wuxiong Chief Bus. Development Officer Sale −107,978 $0.74 $80K 266,467
2026-09-03 Cao Sean Wuxiong Chief Bus. Development Officer Option exercise +235,136 270,209
2026-09-03 Cao Sean Wuxiong Chief Bus. Development Officer Option exercise +104,236 374,445
2026-09-03 Cao Sean Wuxiong Chief Bus. Development Officer Option exercise · Restricted Share Units −102,233 306,700
2026-09-03 Cao Sean Wuxiong Chief Bus. Development Officer Option exercise · Restricted Share Units −45,320 135,960
2026-08-31 Xu Cong Claire EVP, Clinical Development Sale −3,282 $0.79 $3K 304,201
2026-08-30 Xu Cong Claire EVP, Clinical Development Option exercise +9,382 307,483
2026-08-30 Xu Cong Claire EVP, Clinical Development Option exercise · Restricted Share Units −4,079 28,558
2026-08-22 Lenz Robert A. Director Option exercise +17,218 17,218
2026-08-22 Lenz Robert A. Director Option exercise · Restricted Share Units −7,486 14,974
2026-07-08 Hagler Mark Arnold Chief Commercial Officer Grant or award · 2025 Employee Share Option (right to buy) +949,050 949,050
2026-07-08 Lin Liwei Lorraine General Counsel Grant or award · 2025 Employee Share Option (right to buy) +254,780 254,780
2026-07-06 Gupta Srishti Chief Executive Officer Grant or award · 2025 Employee Share Option (right to buy) +3,000,000 3,000,000
2026-07-06 Xu Cong Claire SVP, Clinical Development Sale −4,485 $0.89 $4K 298,101
2026-07-04 Xu Cong Claire SVP, Clinical Development Option exercise +12,432 302,586

Page 1 of 2 · 35 trades